BACKGROUND: There are conflicting data regarding age as a prognostic factor in osteosarcoma. The authors conducted a study evaluating the impact of age on prognosis in children and young adults with osteosarcoma enrolled on North American cooperative group trials. METHODS: Patients with high-grade osteosarcoma of any site enrolled on North American cooperative group trials CCG-7943, POG-9754, INT-0133, and AOST0121 were included in this study. Primary tumor site, age, sex, ethnicity, histologic response, and presence of metastatic disease at diagnosis were evaluated for their impact on overall survival (OS) and event-free survival (EFS). RESULTS: A total of 1054 patients were eligible and had complete data available for the study. Age was not significantly associated with any other presenting covariate analyzed except sex. Age 18 or older was associated with a statistically significant poorer EFS (P = .019) and OS (P = .043). The 10-year EFS and OS in patients <10, 10 to 17, and ≥18 years old were 55%, 55%, 37% and 68%, 60%, 41%, respectively. The poorer EFS in patients ≥18 years old was because of an increased rate of relapse. Presence of metastatic disease at diagnosis, poor histologic response, and pelvic tumor site were also associated with a poorer prognosis. In multivariate analysis, age continued to be associated with poorer EFS (P = .019) and OS (P = .049). CONCLUSIONS: In osteosarcoma, age 18 to 30 years is associated with a statistically significant poorer outcome because of an increased rate of relapse. Poorer outcome in adolescent and young adult patients is not explained by tumor location, histologic response, or metastatic disease at presentation.
BACKGROUND: There are conflicting data regarding age as a prognostic factor in osteosarcoma. The authors conducted a study evaluating the impact of age on prognosis in children and young adults with osteosarcoma enrolled on North American cooperative group trials. METHODS:Patients with high-grade osteosarcoma of any site enrolled on North American cooperative group trials CCG-7943, POG-9754, INT-0133, and AOST0121 were included in this study. Primary tumor site, age, sex, ethnicity, histologic response, and presence of metastatic disease at diagnosis were evaluated for their impact on overall survival (OS) and event-free survival (EFS). RESULTS: A total of 1054 patients were eligible and had complete data available for the study. Age was not significantly associated with any other presenting covariate analyzed except sex. Age 18 or older was associated with a statistically significant poorer EFS (P = .019) and OS (P = .043). The 10-year EFS and OS in patients <10, 10 to 17, and ≥18 years old were 55%, 55%, 37% and 68%, 60%, 41%, respectively. The poorer EFS in patients ≥18 years old was because of an increased rate of relapse. Presence of metastatic disease at diagnosis, poor histologic response, and pelvic tumor site were also associated with a poorer prognosis. In multivariate analysis, age continued to be associated with poorer EFS (P = .019) and OS (P = .049). CONCLUSIONS: In osteosarcoma, age 18 to 30 years is associated with a statistically significant poorer outcome because of an increased rate of relapse. Poorer outcome in adolescent and young adult patients is not explained by tumor location, histologic response, or metastatic disease at presentation.
Authors: P Bieling; N Rehan; P Winkler; K Helmke; R Maas; N Fuchs; S Bielack; U Heise; H Jurgens; J Treuner; R Romanowski; U Exner; R Kotz; K Winkler Journal: J Clin Oncol Date: 1996-03 Impact factor: 44.544
Authors: Paul A Meyers; Cindy L Schwartz; Mark Krailo; Eugenie S Kleinerman; Donna Betcher; Mark L Bernstein; Ernest Conrad; William Ferguson; Mark Gebhardt; Allen M Goorin; Michael B Harris; John Healey; Andrew Huvos; Michael Link; Joseph Montebello; Helen Nadel; Michael Nieder; Judith Sato; Gene Siegal; Michael Weiner; Robert Wells; Lester Wold; Richard Womer; Holcombe Grier Journal: J Clin Oncol Date: 2005-03-20 Impact factor: 44.544
Authors: Holcombe E Grier; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; James S Miser Journal: N Engl J Med Date: 2003-02-20 Impact factor: 91.245
Authors: Matthew T Harting; Kevin P Lally; Richard J Andrassy; Ara A Vaporciyan; Charles S Cox; Andrea Hayes-Jordan; Martin L Blakely Journal: J Cancer Res Clin Oncol Date: 2009-09-27 Impact factor: 4.553
Authors: P A Meyers; G Heller; J Healey; A Huvos; J Lane; R Marcove; A Applewhite; V Vlamis; G Rosen Journal: J Clin Oncol Date: 1992-01 Impact factor: 44.544
Authors: James C Davis; Najat C Daw; Fariba Navid; Catherine A Billups; Jianrong Wu; Armita Bahrami; Jesse J Jenkins; Scott E Snyder; Wilburn E Reddick; Victor M Santana; M Beth McCarville; Junyu Guo; Barry L Shulkin Journal: J Nucl Med Date: 2017-06-13 Impact factor: 10.057
Authors: Scott C Borinstein; Donald A Barkauskas; Mark Bernstein; Allen Goorin; Richard Gorlick; Mark Krailo; Cindy L Schwartz; Leonard H Wexler; Jeffrey A Toretsky Journal: Pediatr Blood Cancer Date: 2013-10-31 Impact factor: 3.167
Authors: Judy Y Ou; Holly Spraker-Perlman; Andrew C Dietz; Rochelle R Smits-Seemann; Sapna Kaul; Anne C Kirchhoff Journal: Cancer Epidemiol Date: 2017-10-07 Impact factor: 2.984
Authors: Lara E Davis; Katherine A Janeway; Aaron R Weiss; Yen-Lin E Chen; Thomas J Scharschmidt; Mark Krailo; Julia L Glade Bender; Lisa M Kopp; Shreyaskumar R Patel; Gary K Schwartz; L Elise Horvath; Douglas S Hawkins; Meredith K Chuk; Denise K Reinke; Richard G Gorlick; R Lor Randall Journal: Cancer Date: 2017-05-11 Impact factor: 6.860